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Narrow Band Ultraviolet B Treatment for Human
Vitiligo Is Associated with Proliferation, Migration,
and Differentiation of Melanocyte Precursors
Nathaniel B. Goldstein1, Maranke I. Koster1,2, Laura G. Hoaglin1,2, Nicole S. Spoelstra3, Katerina J. Kechris4,
Steven E. Robinson5, William A. Robinson5, Dennis R. Roop1,2, David A. Norris1,2 and Stanca A. Birlea1
In vitiligo, the autoimmune destruction of epidermal melanocytes produces white spots that can be repigmented
by melanocyte precursors from the hair follicles, following stimulation with UV light. We examined by
immunoﬂuorescence the distribution of melanocyte markers (C-KIT, DCT, PAX3, and TYR) coupled with markers
of proliferation (KI-67) and migration (MCAM) in precursors and mature melanocytes from the hair follicle and
the epidermis of untreated and narrow band UVB (NBUVB)-treated human vitiligo skin. NBUVB was associated
with a signiﬁcant increase in the number of melanocytes in the infundibulum and with restoration of the normal
melanocyte population in the epidermis, which was lacking in the untreated vitiligo. We identiﬁed several
precursor populations (melanocyte stem cells, melanoblasts, and other immature phenotypes), and progressively
differentiating melanocytes, some with putative migratory and/or proliferative abilities. The primary melanocyte
germ was present in the untreated and treated hair follicle bulge, whereas a possible secondary melanocyte germ
composed of C-KIT+ melanocytes was found in the infundibulum and interfollicular epidermis of UV-treated
vitiligo. This is an exceptional model for studying the mobilization of melanocyte stem cells in human skin.
Improved understanding of this process is essential for designing better treatments for vitiligo, ultimately based
on melanocyte stem cell activation and mobilization.
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INTRODUCTION
Vitiligo is the most common acquired type of leukoderma,
causing signiﬁcant social and psychological difﬁculties in all
patients. The hallmark of the disease is white patches of the
skin, the result of epidermal melanocyte destruction (Picardo
and Taïeb, 2010; Birlea et al., 2012). Melanocyte loss in
vitiligo is caused by immune attack operated by melanocyte-
speciﬁc T cells, innate immunity, and melanocyte-speciﬁc
antibodies (Kemp et al., 2011; Mosenson et al., 2013).
Reversing vitiligo depigmentation is a classic example of
regenerative medicine, requiring activation of hair follicle and
epidermal melanocyte precursors by UV light and/or drugs
(Birlea et al., 2013). Experimental observations in human
vitiligo (Ortonne et al., 1979, 1980; Cui et al., 1991) and
repigmentation transgenic mice models (Nishimura et al.,
2002; Chou et al., 2013; Yamada et al., 2013) have shown
that, during UV exposure, melanocyte precursors proliferate
and migrate along the infundibulum outer root sheath to the
interfollicular epidermis (further referred to as IE or the
epidermis) and repopulate the epidermal areas devoid of
melanocytes. Yet, the cell populations that emerge during
vitiligo treatment and the actual sequence of repigmentation
(proliferation/migration/differentiation) in human vitiligo have
not been described. Despite the progress made in the genetics
of depigmentation (Spritz, 2013), vitiligo repigmentation in
humans remains an enigma, ﬁrst due to the impossibility of
following in real time the melanocyte migration to the
human epidermis, and second because the available mouse
models and human skin equivalents cannot accurately
reproduce the repigmentation process in patients under-
going phototherapy.
To better understand the human repigmentation pathways,
we developed a model using biopsies of untreated and
narrow band UVB (NBUVB)-treated human vitiligo skin in
combination with ﬂuorescent immunostaining to deﬁne and
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analyze the distribution of melanocyte precursors and
differentiated melanocytes in the epidermis and hair follicles.
To conﬁrm some of the immunostaining results, we evaluated
the expression of four pigmentation genes activated during UV
exposure [PAX3, tyrosinase (TYR), dopachrome-tautomerase
(DCT), and KIT]. We show that NBUVB treatment was
associated with increased number of proliferative, putatively
migratory, and differentiating populations of melanocytes in
the infundibulum and the epidermis, supported by a primary
melanocyte germ in the bulge and infundibulum and a
possible secondary germ in the infundibulum and the
epidermis. We also show that long-term intermittent NBUVB
exposure was associated with high activation of pigmentation
genes in the epidermis, as compared with the bulge.
RESULTS
Mapping the key regions of hair follicles
The ﬁrst part of our study was focused on four regions: the
epidermis, hair follicle infundibulum, hair follicle bulge, and
hair follicle bulb (Figure 1). We divided the hair follicle into
four portions from distal to proximal ends: infundibulum
[between the epidermal ostium superiorly and the sebaceous
gland duct inferiorly; Figure 1a], bulge (from the insertion of
sebaceous gland duct above and arrector pili muscle below
(Figure 1b and c)), sub-bulge (proximal to the bulge and distal
to the bulb), and bulb—the base of hair follicle (Figure 1d).
The stem cell population in the bulge was CD200+/K15+; the
arrector pili muscle was desmin+ (Figure 1c). Both CD200
and K15 antibodies were strongly and differentially expressed
in the outer root sheath in cells that adhered to the basement
membrane. Infundibulum outer root sheath cells exhibited a
CD200− /K15− phenotype (Figure 1a).
Immunohistochemical localization of melanocyte antigens
(C-KIT, DCT, PAX3, and TYR) in the epidermis and hair follicles
We tested normal control skin, NBUVB-treated skin, and
untreated vitiligo skin. Our treated vitiligo skin included
samples of perifollicular repigmentation pattern, collected at
two time points (3 and 6 months). We compared the
expression of study markers in the regions tested in four
vitiligo patients treated with NBUVB for 3 months versus four
vitiligo patients treated for 6 months and found similar
expression patterns (P40.05, data not shown), suggesting
that the repigmentation process was already complete by
3 months. As no signiﬁcant variation in melanocyte markers
expression was noted between the two time points, we
included all eight samples in one group of "treated vitiligo" for
the comparison with the untreated samples and with the
normal control skin as well.
We compared all three groups (treated vitiligo, untreated
vitiligo, and normal skin) in regard to markers expression
using one-way analysis of variance. In the infundibulum, all
markers exhibited signiﬁcant variance of expression between
treatment groups (Po0.05; for DCT P=0.05). In the bulge,
markers expression did not vary signiﬁcantly, except C-KIT
(P=0.02). In the bulb, there was no signiﬁcant variance of
marker expression between the three groups.
As shown in Figure 2 (which presents the results of multiple
pairwise post hoc comparisons), the expression of melanocyte
markers in both NBUVB-treated vitiligo skin and normal
control skin was not signiﬁcantly different (adjusted P40.05),
being maximal in the epidermis, and gradually decreasing
toward the bulge. In the untreated vitiligo skin, there were no
melanocytes in the epidermis (Figure 2a, red bars absent), and
there were very few in the infundibulum. NBUVB treatment
was associated with increased expression of melanocyte
markers in the epidermis (one sample t-test, Po0.001),
infundibulum (adjusted Po0.05, except DCT for which
P= 0.05), and bulge (adjusted P40.05), as compared with
the untreated skin (Figure 2a–c and Supplementary Figure S1
online).
The expression of melanocyte markers was signiﬁcantly
higher (Po0.01) in the treated epidermis, as compared with
the treated bulge. Melanocyte marker expression in the
normal skin and treated vitiligo skin was very similar (Figure
2a–c). The bulb of treated and untreated vitiligo and of normal
skin showed a similar expression for melanocyte markers
(Figure 2d).
In all three types of skin tested, TYR expression was absent
in the bulge and lower infundibulum, and appeared only in
the upper infundibulum (not shown), although our statistical
analysis included samples along the entire infundibulum,
between the epidermis and insertion of sebaceous gland duct.
Because the bulb melanocytes (derived from bulge
melanocyte stem cells) were shown to be specialized in
pigmentation of the hair shaft, and the bulge melanocytes to
participate in the vitiligo repigmentation process (Myung and
Ito, 2012), we focused our further experiments on the
epidermis, hair follicle infundibulum, and hair follicle bulge,
regions previously targeted in the mouse repigmentation
models.
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Figure 1. Mapping the anatomic regions of the hair follicle (HF). Anti-human
K15 (green; labels epithelial stem cells) was paired with anti-human desmin
(red; labels the arrector pili muscle (APM)); anti-human CD200 (green; labels
epithelial stem cells) was immunostained by itself. HF infundibulum (INF) (a)
was the region K15− /CD200− located between interfollicular epidermis (IE)
and insertion of sebaceous gland (SG). Bulge (BG) (b and c) was the region
K15+/CD200+ delineated by the SG duct superiorly and by the insertion of
the APM inferiorly. The sub-BG (SBG) was located proximal to the bulge and
distal to the bulb (BB). The bulb (d) was the region K15− /CD200− located at
the base of HF, in which the dermal papilla (DP; delineated with blue line) was
visible internally.
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Distribution of DCT/TYR and C-KIT/TYR phenotypes in the
NBUVB-treated epidermis and hair follicles
We examined the co-localization of C-KIT (present in
immature melanocytes; Grichnik et al., 1996) and DCT
(marker of melanocyte lineage found from the bulge to the
epidermis; Yamada et al., 2013) with TYR (marker of
differentiating melanocytes; Davids et al., 2009). Consistent
small immature populations of C-KIT+/TYR− were found in
NBUVB-treated vitiligo skin in the epidermis, infundibulum,
and bulge (Figure 3a–d). Another immature melanocyte
phenotype (DCT+/TYR− ) was maximal in the bulge, less in
the infundibulum, and almost gone in the epidermis (Figure
3e–h). The expression of more differentiated phenotypes
C-KIT+/TYR+ and DCT+/TYR+ was minimal in the bulge,
more prevalent in the infundibulum, and reached the
maximum in the epidermis.
Distribution of melanocyte stem cells and melanoblasts in the
untreated and NBUVB-treated vitiligo and their proliferative
potential
Figure 4a and c represent the melanocyte stem cells (the most
immature population of melanocyte, carrying the phenotype
C-KIT− /DCT+) and the melanoblasts (an immature popula-
tion of melanocytes, carrying the phenotype C-KIT+/DCT+,
which are more differentiated than the melanocyte stem cells;
Yamada et al., 2013). Both phenotypes were abundant in the
untreated and treated infundibulum and bulge. In all regions
tested of treated vitiligo, the melanoblasts were the majority
population and also showed the highest proliferative capacity,
as compared with the other C-KIT/DCT phenotypes. We also
observed small subpopulations of proliferative melanocyte
stem cells (C-KIT− /DCT+/KI-67+) in the treated and untreated
bulge, and in untreated infundibulum, and proliferative
melanoblasts (C-KIT+/DCT+/KI-67+) in the untreated bulge.
The large percentage of melanocytes that were DCT+/C-KIT+
in the epidermis and infundibulum of treated vitiligo skin
argue against all of these cells being melanoblasts. Interestingly,
in the infundibulum of untreated skin, the subpopulation of
proliferative melanoblasts was absent. The phenotype with
unknown function C-KIT+/DCT− was similarly distributed
along the hair follicle and the epidermis of treated skin, and
higher expressed in all regions, as compared with untreated
skin. Figure 4b illustrates some of the representative cell
populations enumerated here.
In addition to the above data, our analysis of the normal
control skin indicated a similar expression pattern for DCT,
C-KIT, and KI-67 as compared with NBUVB-treated vitiligo
skin (not shown).
Melanocyte migration and proliferation in the untreated and
NBUVB-treated vitiligo
We next focused our analysis on the co-expression of DCT
with MCAM (melanoma cell adhesion molecule, previously
associated with melanocytic cell migration; Medic and
Ziman, 2010; Medic et al., 2011) and the proliferation
marker KI-67 (Figure 5a and bi). In the NBUVB-treated
vitiligo, we identiﬁed a non-proliferative and presumably
migratory population (DCT+/MCAM+/KI-67− ; Figure 5bi),
which was similarly represented in the epidermis and
infundibulum of treated skin and was nonsigniﬁcantly lower
in the treated bulge. We also found a small proliferative
and putatively mobile population DCT+/MCAM+/KI-67+
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Figure 2. Graphical representation of melanocyte markers expression (PAX3, tyrosinase (TYR), dopachrome-tautomerase (DCT), and C-KIT). Marker
expression was tested in interfollicular epidermis (IE) (a), hair follicle infundibulum (INF) (b), hair follicle bulge (BG) (c), and hair follicle bulb (BB) (d) of untreated
vitiligo skin (red bars), narrow band UVB (NBUVB)-treated vitiligo skin (blue bars), and normal control skin (green bars). Signiﬁcant differences in expression were
observed for all markers in the epidermis (a) and some markers in the INF (b) of untreated vitiligo skin, as compared with NBUVB-treated or with normal skin. No
signiﬁcant differences were observed in the BG (c) and BB (d) of untreated vitiligo skin, as compared with NBUVB-treated vitiligo skin or with normal skin, except
for C-KIT expression in the untreated BG compared with normal skin. (Po1.0E-03 (*); 1.0E-03⩽P⩽5.0E-02 (#); all other comparisons showed P45.0E-02 (not
signiﬁcant)). One-way analysis of variance with Tukey’s multiple comparisons tests were used for statistical comparison. Each bar represents mean± SEM (n=4,
untreated vitiligo patients; n= 8, NBUVB-treated vitiligo patients).
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(Figure 5bi) in greatest proportion in the treated epidermis but
also present in the treated infundibulum and bulge. In the
treated skin, the majority of DCT+ melanocytes were non-
migratory and non-proliferative (DCT+/MCAM− /KI-67− ).
The migratory and proliferative phenotypes were similar in
the bulge of treated (Figure 5bi) and untreated vitiligo (not
shown). In the infundibulum of untreated vitiligo skin, the
putatively migratory populations were absent (not shown).
In addition, MCAM expression in the DCT+ cells was
signiﬁcantly lower (P⩽0.05) in the epidermis and hair
follicles of normal control skin as compared with the treated
vitiligo skin (not shown).
Melanocyte differentiation coupled with proliferation and
migration in the untreated and NBUVB-treated skin
We examined the co-expression of TYR (marker of melano-
cyte differentiation) with MCAM and KI-67 in the infundibu-
lum and the epidermis of NBUVB-treated vitiligo (Figure 5bii
and c) and in untreated skin (not shown). We did not
analyze the bulge because of the absence of TYR. We found
two phenotypes, each expressed in more than 1/3 of the
TYR+ cells: a differentiating, putatively immobile, and
non-proliferative phenotype (TYR+/MCAM− /KI-67− ;
Figure 5bii), which was highly expressed in the treated skin,
and a differentiating, putatively migratory, non-proliferative
phenotype (TYR+/MCAM+/KI-67− ; Figure 5bii). In addition,
we identiﬁed a small differentiating, proliferative, and
migratory population TYR+/MCAM+/KI-67+ (Figure 5bii) in
the epidermis and infundibulum that represented o10% of
total melanocytes. In contrast to the treated skin, the untreated
infundibulum showed very few TYR-positive cells (Figure 2b),
which did not express MCAM or KI-67.
Differential gene expression in the hair follicle bulge and
epidermal melanocytes of the NBUVB-treated vitiligo
To see whether changes in the levels of melanocyte proteins
C-KIT, DCT, PAX3, and TYR correlate with changes in gene
expression, we examined the activation of genes encoding
these proteins in three vitiligo patients treated 3 months with
NBUVB (Supplementary Figure S2 online). We performed
ﬂuorescent laser capture microdissection of melanocytes
located in the hair follicle bulge and the epidermis (panel a).
Total RNA was extracted and then subjected to quantitative
real-time reverse-transcriptase–PCR (qRT-PCR). For each
individual sample, we observed a similar trend of remarkable
upregulation in the epidermis as compared with the paired
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Figure 3. Distribution of C-KIT/tyrosinase (TYR) and dopachrome-tautomerase (DCT)/TYR populations in the interfollicular epidermis (IE) and hair follicles
(HFs). Narrow band UVB (NBUVB)-treated skin sections, showing expression of melanocyte markers: anti-TYR (green) combined with either anti-C-KIT (red) or
anti-DCT (red). Anti-K14 (blue) labeled basal keratinocytes. The precursor phenotypes––(C-KIT+/TYR− ) and (DCT+/TYR− )––are shown by red arrows and the
differentiated phenotypes––(C-KIT+/TYR+) and (DCT+/TYR+)––by green arrows in the IE (a and f), infundibulum (INF) (b and g), and bulge (BG) (c and h).
Graphical representation in the regions tested of percent (C-KIT+/TYR− ) precursors (red bars) and (C-KIT+/TYR+) differentiated cells (green bars) (d); percent
(DCT+/TYR− ) precursors (red bars) and (DCT+/TYR+) differentiated cells (green bars) (e). Each bar represents mean± SEM (n= 8, NBUVB-treated vitiligo
patients). White bars=100 μm, yellow bars=25 μm.
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bulge sample (panel bi). When the results from the three
samples were averaged (panel bii), there was a greater
increase in TYR expression (~52-fold higher in the epidermis
vs. bulge), compared with the increase in KIT (~10-fold), DCT
(~14-fold), or PAX3 (~3-fold) expression in the epidermis
versus bulge. However, when all three samples were
analyzed together, the higher expression in the IE compared
with the bulge was signiﬁcant for DCT (P=0.03) and
nonsigniﬁcant for TYR (P=0.05), PAX3 (P=0.08), and KIT
(P= 0.16).
NBUVB was associated with several melanocyte populations
exhibiting proliferative, migratory, and differentiating abilities
in vitiligo lesions
By combining the results of immunostaining experiments,
we identiﬁed four main melanocyte populations in the
UV-treated vitiligo skin, as presented in Figure 6 and in
Supplementary Tables S3 and S4 online: a melanocyte stem
cell population A (C-KIT− /DCT+/TYR− ), a melanoblast
population C (C-KIT+/DCT+TYR− ), a population of differ-
entiating cells D (C-KIT+/DCT+/TYR+), and a persistent
population with unknown function B (C-KIT+/DCT− /TYR− ).
We identiﬁed the following: (i) immature populations of
melanocytes A and melanoblasts C in the treated and
untreated bulge, with small proportions of proliferative KI-67+
(A1 and C1) and/or putatively migratory MCAM+ (A2 and C2)
subpopulations; the proportions of A and C populations
increased nonsigniﬁcantly during NBUVB; (ii) a dominant
immature melanoblast population C in the infundibulum of
untreated skin, putatively immobile and non-proliferative.
NBUVB treatment was associated with the expansion of the C
phenotype and with the emergence of presumably mobile
and proliferative subpopulations (C1, C2) in the treated
infundibulum; (iii) very few differentiating melanocytes D in
the untreated infundibulum, which lacked markers of prolifera-
tion and migration. A dominant, highly expanded phenotype
D in the NBUVB-treated infundibulum, which contained
subpopulations with markers of proliferation and migration
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Figure 4. Distribution of melanocyte stem cell and melanoblast phenotypes and their proliferative capacity. (a) Untreated vitiligo: graphical representation
of percent of melanoblast phenotype (C-KIT+/DCT+) (ai), C-KIT+/DCT− phenotype (aii), and melanocyte stem cell phenotype (C-KIT− /DCT+) (aiii) per total
melanocytes (MC) in interfollicular epidermis (IE), infundibulum (INF), and bulge (BG). The most prevalent in INF and BG were non-proliferative melanoblasts
(DCT+/C-KIT+/KI-67− ; yellow bars, ai) and non-proliferative stem cells (DCT+/C-KIT− /KI-67− ; green bars, aiii). Small subpopulation of proliferating
melanoblasts DCT+/C-KIT+/KI-67+ are shown in the BG (white bar, ai). Small proliferative population of melanocyte stem cells (DCT+/C-KIT− /KI-67+) shown in
the BG and IFN (light-green bars, aiii). (b) Narrow band UVB (NBUVB)-treated vitiligo: representative images of immunostaining in the IE and hair follicle,
showing expression of anti-KI-67 (blue) combined with anti-C-KIT (red) and anti-DCT (green). Red arrows in the INF (bii) and red bars (cii) indicate cells that
expressed only C-KIT (non-proliferating MC). The blue arrow shows cells that expressed only the KI-67 marker (likely keratinocytes) (bi and bii). Yellow
Bar=25 μm. (c) NBUVB-treated vitiligo: graphical representation of percent melanoblasts (C-KIT+/DCT+) (ci), C-KIT+/DCT− phenotype (cii), and the stem cells
(DCT+/C-KIT− ) (ciii) per total MC in IE, INF, and BG. The most prevalent phenotype observed in all three regions tested was non-proliferative (DCT+/C-KIT
+/KI-67− ) (bi, yellow arrow, and ci, yellow bars). A small population of proliferating MC DCT+/C-KIT+/KI-67+ decreased from the epidermal surface
with the depth of the INF (ci, white bars, bi, white arrows). Each bar represents mean± SEM (n= 5, untreated vitiligo patients; n=5, NBUVB-treated vitiligo
patients).
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(D1, D2); (iv) a phenotype C-KIT+/DCT+, also TYR+ (D),
present in almost all melanocytes emerged during NBUVB in
the depigmented epidermis, containing putatively mobile
proliferative or non-proliferative subpopulations (D1, D2) but
also a dominant differentiating, non-migratory and non-prolife-
rative subpopulation C-KIT+/TYR+/DCT+/MCAM− /KI-67− .
About 10% of the differentiated melanocytes in the epidermis
and infundibulum were KI-67+; (v) a small population B
of C-KIT+/DCT− phenotype, in all regions with melano-
cytes, which represented about 5% of the total in the
NBUVB-treated skin and contained small subpopulations
of KI-67+ or MCAM+ cells (Figure 4 and Supplementary
Table S4 online).
DISCUSSION
In this study, we tried to provide a better understanding of
the repigmentation process in vitiligo. Our work studied the
perifollicular pattern of repigmentation, because this was the
most commonly observed in our clinic. The predominance of
this pattern claimed by us and others (Parsad et al., 2004;
Yang et al., 2010) suggests that the hair follicle is the main
reservoir that supplies melanocytes in repigmenting human
vitiligo. Other patterns, like marginal and diffuse repigmentation
(rarely observed by us and less often than the perifollicular
pattern by others (Yang et al., 2010)), suggest the presence of a
secondary reservoir, possibly derived from the more immature
basal melanocytes located at the lesional borders.
Our immunostaining study showed that the hair follicle
bulge of treated and untreated vitiligo and the untreated
infundibulum contained only amelanotic melanocytes (i.e.,
they expressed the melanocyte markers DCT and/or C-KIT
and/or PAX3, but they were TYR− and Fontana-Masson-;
Figures 2,3,4 and Supplementary Figures S1 and S3 online).
Fontana-Masson+ cells and TYR+ cells were seen only in the
upper infundibulum and the epidermis of treated skin
(Supplementary Figures S1 and S3 online). NBUVB treatment
was associated with signiﬁcantly increased expression of
melanocyte markers in the vitiligo spots, the most striking
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Figure 5. Assessment of putatively migratory (melanoma cell adhesion molecule (MCAM+)), differentiating (tyrosinase (TYR)+), and proliferative (KI-67+)
phenotypes. (a) Representative immunostaining pictures of narrow band UVB (NBUVB)-treated vitiligo showing expression of markers in the interfollicular
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Triple-positive cells (DCT+/MCAM+/KI-67+) are presented in the merged image (gray arrows), as well as one cell DCT+ only (green arrow). Yellow bar= 25 μm.
(b) Graphical representation of the percent presumably migrating (MCAM+) and non-migrating (MCAM− ) melanocytes co-expressing DCT and KI-67 (bi) or TYR
and KI-67 (bii) per total melanocytes in IE, infundibulum (INF), and bulge (BG) of NBUVB-treated vitiligo skin. bi shows a large population of putatively non-
migratory and non-proliferative DCT+/MCAM− /KI-67− cells in all three regions (green bars), an increasing population of presumably migrating but non-
proliferating melanocytes (DCT+/MCAM+/KI-67− ) from the BG to the IE (yellow bars), and a small population of putatively migrating proliferative melanocytes
(DCT+/MCAM+/Ki-67+) highest in the IE (gray bars). bii shows similar trends for TYR. The BG was not analyzed for TYR as the melanocytes were TYR− . Each bar
represents mean± SEM. (c): Representative immunostaining images of NBUVB-treated vitiligo showing expression of markers in the INF: anti-KI-67 (blue image,
blue arrows) combined with anti-MCAM (red image, red arrows) and anti-TYR (green image, green arrows). A single triple-positive cell is seen in the merged
image (white arrow), as well as two TYR+ cells (green arrows) and a KI-67+ keratinocyte (blue arrow). Each bar represents mean± SEM (n= 5, NBUVB-treated
vitiligo patients). Yellow bar=25 μm.
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contrast being observed between the untreated depigmented
epidermis (devoid of melanocytes) and the treated pigmented
epidermis, which was heavily DCT+, C-KIT+, PAX3+, TYR+,
and strongly Fontana-Masson+ (Supplementary Figures S1
and S3 online). The increase in melanocyte marker expression
was reﬂected by an increase in cell numbers, and also in
staining intensity, which was high in the treated epidermis
and weaker in the treated and untreated hair follicle bulge
(Supplementary Figure S1 and S3 online). In the treated
epidermis, the markers expression was signiﬁcantly elevated
as compared with the treated bulge, and this result was
paralleled at the transcription level by our qRT-PCR analysis
(Supplementary Figure S2b online). The results of our gene
expression analysis are consistent with the function of these
pigmentation genes. Both DCT and TYR, genes coding for
proteins that control melanogenesis, were highly increased in
the epidermis of NBUVB-treated vitiligo skin, reﬂecting high
production of melanin here. KIT, with attributed roles in
melanocyte proliferation and migration, was also higher
expressed in the epidermis (compared with the bulge). PAX3
showed slight increase in expression in the epidermis
compared with the bulge, consistent to the fact that it is a
transcription factor gene with rapid ﬂuctuations and which
can alternatively activate and downregulate downstream
pigmentation genes (Kubic et al., 2008). Our observation of
the low expression of pigmentation genes in the bulge veriﬁed
previous studies (Nishimura et al., 2010), attributing the
inhibitory role of gene transcription to TGF-β signaling, which
maintains melanocyte stem cell immaturity and quiescence in
the bulge.
We found no difference in melanocyte marker expression
between NBUVB-treated and normal skin (Figure 2 and
Supplementary Table S1 online). This observation indicates
that NBUVB exposure for 3–6 months can bring the depig-
mented skin to an apparently normal status.
Our human vitiligo model revealed a similar distribution
of “melanoblast” (C-KIT+/ DCT+) and “melanocyte stem cell”
(C-KIT− /DCT+) phenotypes (Figure 4), as was previously
reported in mice (Yamada et al., 2013). Like Yamada, we
assume that the (C-KIT− /DCT+) phenotype labeled melano-
cyte stem cells because of its almost exclusive location in the
bulge and because DCT is a lineage marker expressed in
melanocyte precursors earlier than C-KIT (Nishimura et al.,
2002). However, in our model, the C-KIT+/DCT+ population
included a broader stage than the immature “melanoblast” that
was earlier described by Yamada et al., 2013.
In our study, melanocyte proliferation after NBUVB was
indirectly reﬂected by the observation of increased melano-
cyte numbers in all regions tested (Figure 2) and was directly
quantiﬁed by KI-67 co-expression with C-KIT, DCT, and TYR
(Figures 4 and 5). Melanocyte proliferation was nonsigniﬁ-
cantly higher in the bulge of treated skin (as compared with
the untreated skin) and was signiﬁcantly higher in the
infundibulum and the epidermis. These results are in accord
with our recent studies on UV-induced DNA damage,
showing that single-dose NBUVB irradiation on human skin
penetrates the hair follicle and induces cellular changes in
Precursors
Precursors
INF
IE
BG
Differentiating
Differentiating
Untreated vitiligo
DCT+
A BC-KIT–/DCT+/TYR– C-KIT+/DCT–/TYR– C-KIT+/DCT+/TYR–
C-KIT–/DCT+/TYR–/KI-67+/MCAM–
C-KIT–/DCT+/TYR–/KI-67–/MCAM+
C-KIT+/DCT+/TYR–/KI-67+/MCAM–
C-KIT+/DCT+/TYR–/KI-67–/MCAM+
C-KIT+/DCT+/TYR+
C-KIT+/DCT+/TYR+/KI-67+/MCAM+
C-KIT+/DCT+/TYR+/KI-67–/MCAM+
A1
A2
C
C1
C2
D
D1
D2
C-KIT+ C-KIT+/DCT+ C-KIT+/DCT+/TYR+
Treated vitiligo
D
DD
D2
D2
D1
D1
C
CC
C C
C1
C1
C1C1
C2
C2C2
B
BB
B B
A
A
A
A2
A2 A2A1A1
A1
A
Figure 6. Diagram of melanocyte precursors and more differentiated phenotypes in treated and untreated vitiligo. The precursors and more differentiated
phenotypes are represented with different colors in the bulge (BG), infundibulum (INF), and interfollicular epidermis (IE). The relative diameter of each circle in
each study region represents the estimated percent of melanocytes exhibiting particular phenotypes in each study region, normalized to the average number of
melanocytes in each region (melanocyte percentages presented in the Figure 2 and Supplementary Table S1 online). Percentages of each phenotype and circle
diameters are summarized in the Supplementary Tables S3 and S4 online.
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the bulge, as well as in more superﬁcial regions of the skin
(White et al., 2013). Two recent studies on transgenic mice
(Chou et al., 2013; Yamada et al., 2013) also reported
melanoblast or melanocyte proliferation in the hair follicle
and/or the epidermis induced by stimuli like UVB or wounds
created in the mouse skin.
Although we have not yet been able to follow melanocyte
migration in real time, we evaluated the putatively migratory
capacity more indirectly through immunostaining (Figure 5).
We identiﬁed a presumed migratory population of melano-
cytes (DCT+/MCAM+) that was minimally expressed in the
bulge and of which expression increased in the infundibulum
and the epidermis. Two studies (Nishimura et al., 2002; Chou
et al., 2013) utilized direct labeling of melanocytes (carrying
the DCT-LacZ+ mutation) to demonstrate the melanocyte
migration from the bulge to the epidermis induced by different
stimuli (like forced Slf expression in epidermal keratinocytes
carrying the Slf-K14 transgene, UVB exposure, or wounds
created on the mouse skin). More recently, the results of an
immunostaining study of human vitiligo skin (Kovacs et al.,
2015) suggested the migratory capacity of melanocytes
(horizontal migration to depigmented areas) in response to
punch grafting followed by treatment with Khellin+UV light.
In our model, the melanocyte precursors showed differ-
entiation abilities in the upper infundibulum by gradually
exhibiting TYR expression, a process that paralleled prolifera-
tion and migration and that continued in the epidermis
(population TYR+/MCAM+/KI-67+; Figure 5b and c). A
similar robust melanocyte maturation process (induced by
different stimuli, like UVB exposure, or by forced expression
of Slf in the epidermis) was described in the hair follicle
melanoblasts and epidermal melanocytes of different trans-
genic mouse models (Nishimura et al., 2002; Chou et al.,
2013; Yamada et al., 2013).
Our study suggests a possible association of the following
observations (also represented in the Figure 6) with NBUVB
treatment: (i) a nonsigniﬁcant increase in the expression of
precursor populations in the bulge; (ii) a noticeable increase
in the expression of the melanocyte differentiating phenotype
D in infundibulum, the emergence of phenotype D in
epidermis, as well as the emergence of proliferative and
migratory differentiating subpopulations D1 and D2 in both
infundibulum and the epidermis; (iii) the emergence of
subpopulations of putatively mobile and proliferative mela-
noblasts (C1, C2) in the infundibulum; (iv) a gradual decrease
in melanocyte precursors from the bulge to the epidermis,
which suggests a possible role of NBUVB in maturation of
epidermal melanocytes; (v) the absence of the classical stem
cell population A (C-KIT/DCT+/TYR) as the only putative
precursor population identiﬁed in the epidermis, which might
represent a secondary melanocyte germ there and in the
upper infundibulum. As we discussed above, the hypothesis
of an intra-epidermal reservoir of melanocytes has been
previously claimed based on clinical (Yang et al., 2010) but
also experimental observations (Grichnik et al., 1996; Davids
et al., 2009), although clariﬁcation of this aspect is awaited
through future experiments.
In sum, the presence of small subsets of KI-67+ and/or
MCAM+ cells of melanocyte lineage (DCT+) in the melano-
cyte stem cell, melanoblast, and differentiated melanocyte
populations supports the concept that proliferation and
migration within the bulge, infundibulum, and the epidermis
are essential for the development of the large population of TYR+
melanocytes in the epidermis of NBUVB-treated vitiligo. A
signiﬁcant subpopulation of TYR-proliferating melanoblasts is
not found in the treated epidermis, supporting the view that
the proliferating cells that repopulate depigmented vitiligo
epidermis arise in a TYR+ population in the upper infundi-
bulum and the epidermis. We propose that NBUVB treatment
is associated with a stepwise proliferation and migration from
the bulge to the epidermis: proliferation and migration of
melanocyte stem cells, then melanoblasts, and then differ-
entiating TYR+melanocytes. The upper infundibulum is a key
site of melanoblast differentiation to TYR+ cells; these cells
then continue to proliferate and migrate to the epidermis. Once
they reach the epidermis, they can continue to proliferate,
migrate, and, in addition, to terminally differentiate, as part of
the major epidermal melanocyte population.
Our human model and previous animal models support
the concept that the hair follicle bulge is the location of
melanocyte stem cells that are the major precursors for the
melanocyte repopulation of the epidermis.
MATERIALS AND METHODS
Sample collection
Skin biopsies were performed at the Dermatology Clinic at University
of Colorado Hospital. Written informed consent was obtained from
all subjects, and the study was approved by Human Subjects
Committee (COMIRB) at the University of Colorado.
Mapping the key regions of the hair follicle
Both parafﬁn and frozen transversal sections were immunostained for
the hair follicle bulge and infundibulum mapping with anti-CD200,
anti-K15, and anti-Desmin antibodies using every 10th slide accord-
ing to established methods.
Antibodies and immunohistochemistry
The primary and secondary antibodies used are listed in the
Supplementary Materials and Methods online, and standard proce-
dures were used for immunohistochemistry.
Statistical analysis
For each sample, quantiﬁcation of cells positive for a given marker
was done, and the differences in percentages for each site/marker
were analyzed, as presented in the Supplementary Materials and
Methods online.
To build the Venn diagram (Figure 6), we used the raw data generated
by our 2- and 3-marker immunostaining assays (Supplementary Table
S5 online) and a fractional factorial design (Box et al., 2005; Collins
et al., 2009) to impute summary statistics of the 2-, 3-, 4-, and 5-marker
combinations that were not possible to measure directly.
Fluorescent laser capture microdissection
We captured 100 individual melanocytes from the epidermis and
hair follicle bulge using frozen sections of three NBUVB-treated
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vitiligo patients. Sections were rapidly immunostained using a mouse
monoclonal antibody to NKI-beteb (Horikawa et al. 1996).
RNA extraction and qRT-PCR
Total RNA was extracted from the laser captured melanocytes and
then ampliﬁed, as described in the Supplementary Materials and
Methods online. qRT-PCR was performed with primers designed
by ourselves and standard procedures. Primer pairs are shown in
Supplementary Table S2 online.
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